Physician profile
Ammar Nasir
NPI 1427212299
$2,397.75
in general payments reported to CMS, 2019-2025
16 companies · $776 in 2025
The $776 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $145 · 2020: $151 · 2021: $99.09 · 2022: $150 · 2023: $63.13 · 2024: $1,013 · 2025: $776.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,852.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,851.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $382.70 | 2024-2025 | Impella |
| Medtronic, INC. | $333.03 | 2022-2025 | Corevalve Evolut R, Onyx Frontier, Symplicity G3 |
| Shockwave Medical, INC | $250.83 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Edwards Lifesciences Corporation | $247.82 | 2024-2025 | Sapien 3 Ultra Resilia |
| Cardiovascular Systems INC. | $204.03 | 2019-2022 | |
| Abbott Laboratories | $192.59 | 2023-2024 | Amplatzer Amulet, Assurity, Perclose Prostyle |
| Pfizer INC. | $184.03 | 2024-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $181.99 | 2023-2025 | Lifevest |
| Medtronic Vascular, INC. | $124.53 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $82.30 | 2025 | Eliquis |
| Cvrx, INC. | $58.31 | 2024-2025 | Barostim Neo System |
| Biosense Webster, INC. | $50.00 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $41.16 | 2024 | Brilinta |
| Terumo Medical Corporation | $29.35 | 2025 | Tr Band |
| Penumbra, INC. | $20.00 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $15.08 | 2024 | Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ammar Nasir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.